hidradenitis suppurativa
Dermatology · 2016–2025
12decisions
3medicines
8carried consumer input
29individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Treatment of immune-mediated inflammatory diseases (IMIDs) in paediatric patients under 18 years of age, with disease severity considered sufficient to cause… | Jul 2025 | Recommended with restriction | 6 individuals |
| bimekizumab Treatment of patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic HS therapy. | May 2025 | Recommended with restriction | 2 individuals |
| secukinumab Treatment of moderate to severe hidradenitis suppurativa (HS) in adult patients who have failed to achieve an adequate response to at least 2 courses of… | Jul 2023 | Not recommended | 7 individuals |
| secukinumab Treatment of moderate to severe hidradenitis suppurativa in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa… | Nov 2023 | Recommended with restriction | none received |
| adalimumab Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa, chronic plaque psoriasis, ulcerative colitis, Crohn's disease, and… | Nov 2022 | Not recommended | 1 individuals |
| adalimumab Treatment of moderate to severe hidradenitis suppurativa (HS) in adult patients, using 80 mg fortnightly maintenance dosing following induction treatment. | Nov 2019 | Recommended | none received |
| adalimumab Treatment of moderate to severe hidradenitis suppurativa in adult patients, specifically for maintenance dosing following induction treatment with the 80 mg… | Nov 2019 | Recommended | none received |
| adalimumab Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile idiopathic arthritis, severe… | Jul 2018 | Recommended | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| adalimumab Initial treatment of moderate-to-severe hidradenitis suppurativa in adult patients with inadequate response to conventional systemic therapy. | Jul 2016 | Not recommended | 1 individuals |
| adalimumab Initial treatment of moderate-to-severe hidradenitis suppurativa (HS) in adult patients with inadequate response to conventional HS therapy. | Mar 2016 | Not recommended | 7 individuals |
| adalimumab Treatment of moderate to severe hidradenitis suppurativa in adult patients with an inadequate response to conventional systemic therapy, after failure of at… | Nov 2016 | Deferred | 4 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 8 of 12 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.